Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects

American Journal of Cardiovascular Drugs

Volumn 11, Issue 5, 2011, Pages 335-346

  Chi, Yong Ha ^a   Lee, Howard ^b,c   Paik, Soo Heui ^a   Lee, Joo Han ^a   Yoo, Byoung Wook ^a   Kim, Ji Han ^a   Tan, Hyun Kwang ^a   Kim, Sang Lin ^a  

^a Boryung Pharm Co Ltd   (South Korea)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of California Washington Center   (United States)

Author keywords

Fimasartan

Indexed keywords

ANGIOTENSIN I; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE; FIMASARTAN;

ALDOSTERONE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEEDING; FOOD; FOOD DRUG INTERACTION; HEMATOLOGY; HUMAN; MAXIMUM PLASMA CONCENTRATION; PHARMACODYNAMICS; PHYSICAL EXAMINATION; PLASMA CONCENTRATION-TIME CURVE; PLASMA RENIN ACTIVITY; POSITIONAL DIZZINESS; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SYNCOPE; SYSTOLIC BLOOD PRESSURE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINALYSIS;

ADMINISTRATION, ORAL; ADULT; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FOOD-DRUG INTERACTIONS; HALF-LIFE; HUMANS; INTESTINAL ABSORPTION; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PYRIMIDINES; RENIN; TETRAZOLES; YOUNG ADULT;

EID: 80052737386     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11593840-000000000-00000     Document Type: Article

References (20)

1. Sohn Y. Crystal forms of an angiotensin II receptor antagonist BR-A657 J Therm Anal Cal 2007; 89 (3): 799-802 (Pubitemid 47351774)
2. Boryung Pharm Co. Ltd SK. Label for Kanarb (fimasartan potassium).Data on file, 2010
3. Boryung Pharm Co. Ltd SK. Investigator's brochure for fimasartan. Data on file, 2006
4. Hollenberg NK, Guidi E. ACE inhibitors and renal vascular responses in the spontaneously hypertensive rat. J Cardiovasc Pharmacol Ther 1998; 3 (2): 161-70 (Pubitemid 29131894)
5. Lane A, Engmann E, Bryson S, et al. Single dose pharmacokinetics (PK) and pharmacodynamics (PD) of BR-A-657, an angiotensin II (AII) antagonist [abstract]. Clin Pharmacol Ther 2005; 77 (2): 59
6. Lane A, Kleinermanns D, Bryson S, et al. Multiple dose pharmacokinetics (PK) and pharmacodynamics (PD) of BR-A-657, an angiotensin II (AII) antagonist [abstract]. Clin Pharmacol Ther 2005; 77 (2): 58
7. Boxenbaum H, Battle M. Effective half-life in clinical pharmacology. J Clin Pharmacol 1995; 35 (8): 763-66
8. Hummel J, McKendrick S, Brindley C, et al. Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. Pharm Stat 2009; 8 (1): 38-49
9. Brown H, Prescott R. Applied mixed models in medicine. Wiley, West Sussex, England, 2006
10. Catt KJ, Cain MD, Zimmet PZ, et al. Blood angiotensin II levels of normal and hypertensive subjects. Br Med J 1969; 1 (5647): 819-21
11. Goldberg MR, Bradstreet TE, McWilliams EJ, et al. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the reninangiotensin- aldosterone system in hypertensive patients. Hypertension 1995; 25 (1): 37-46
12. Criscione L, Bradley WA, Buhlmayer P, et al. Valsartan: preclinical and clinical profile of an antihypertensive angiotensin-II antagonist. Cardiovasc Drug Rev 1995; 13 (3): 230-50 (Pubitemid 26110791)
13. Kaplan NM. Angiotensin II-receptor blockers: will they replace angiotensinconverting enzyme inhibitors in the treatment of hypertension? J Hum Hypertens 2000; 14 Suppl. 1: S87-90 (Pubitemid 30406524)
14. Reid IA, Morris BJ, Ganong WF. The renin-angiotensin system. Annu Rev Physiol 1978; 40: 377-410 (Pubitemid 8351313)
15. Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000; 14 Suppl. 1: S73-86 (Pubitemid 30409970)
16. Pedersen PV, Miller R. Pharmacokinetics and bioavailability of cimetidine in humans. J Pharm Sci 1980; 69 (4): 394-8 (Pubitemid 10079747)
17. Zhou H. Pharmacokinetic strategies in deciphering atypical drug absorption profiles. J Clin Pharmacol 2003; 43 (3): 211-27 (Pubitemid 36232649)
18. Veng PP. Pharmacokinetic analysis by linear system approach. I: Cimetidine bioavailability and second peak phenomenon. J Pharm Sci 1981; 70 (1): 32-8
19. Beermann B. Value of plasma-digoxin estimation [letter]. Lancet 1973; 1 (7799): 375
20. Sheiner LB, Stanski DR, Vozeh S, et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979; 25 (3): 358-71 (Pubitemid 9164953)